Health AI Central
Share:
Peer-Reviewed Publication
Gastroenterology2026;170(3):595-605.March 1, 2026Journal Article

Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.

Grishma Hirode1, Hooman F Zangneh2, Orlando Cerocchi2, Korosh Khalili3, Lima A El-Karim3, Christopher Kandel4, Mara Vecchio5, Jeffrey Winick5, Yasuhiro Mori6, Hiroyuki Yamada6, Harry L A Janssen7, Bettina E Hansen8, Morris Sherman2, Jordan J Feld9
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; The Viral Hepatitis Care Network Canada (VIRCAN), Toronto, Ontario, Canada.
2Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
3Joint Department of Medical Imaging, University Health Network, Toronto, Ontario, Canada.
4Michael Garron Hospital, Division of Medicine, Toronto, Ontario, Canada; University of Toronto, Faculty of Medicine, Toronto, Ontario, Canada.
5FUJIFILM Healthcare Americas Corporation, Plano, Texas.
6FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan.
7Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands.
8Department of Epidemiology, Biostatistics, Erasmus University Medical Center, Rotterdam, Netherlands.
9Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; The Viral Hepatitis Care Network Canada (VIRCAN), Toronto, Ontario, Canada. Electronic address: jordan.feld@uhn.ca.
PubMed DOI

Abstract

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) surveillance is key to early diagnosis and timely curative treatment. Current strategies are suboptimal with many patients presenting with advanced HCC. This randomized controlled trial compared the combined use of serum biomarker (BM) measurements and abdominal ultrasound (US) with US alone for the diagnosis of early-stage HCC. METHODS: Adults wi…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.